tag@treatmentactiongroup.org

HCV

Letter to Hillary Clinton on HCV Drug Prices

  • Chad Cipiti
Dear Secretary Clinton, As a national group of healthcare providers, advocates, and patients dedicated to preventing and treating viral hepatitis, we welcome your recent comments in Cleveland regarding the high price of pharmaceutical drugs to cure the hepatitis C virus (HCV). We are encouraged by the broad support for government action on the high price of pharmaceutical drugs, especially those for viral hepatitis, and to see this issue being directly addressed by elected officials at all levels of government. However, we are writing you today out of concern that your current healthcare platform does not specifically or adequately address the national and international viral hepatitis epidemics. We must work together to raise the profile of hepatitis B and C as urgent public health priorities.
Read more

Epclusa Fact Sheet

  • Chad Cipiti
Epclusa is a fixed-dose combination of two HCV-fighting drugs (sofosbuvir and velpatasvir) in one pill. In the United States, Epclusa is approved for people with all hepatitis C genotypes (1–6) who are 18 years of age and older.
Read more

Zepatier Fact Sheet

  • Chad Cipiti
Zepatier is two hepatitis C virus-fighting drugs in one tablet. These drugs block different steps of the virus lifecycle. In the United States, Zepatier is approved for people who are over 18 years old with hepatitis C genotype 1 or genotype 4.
Read more

Solvaldi Fact Sheet

  • Chad Cipiti
Sovaldi (sofosbuvir) is an HCV-fighting drug that must be used with other drugs. In the United States, Sovaldi is approved for people with hepatitis C genotypes 1, 2, 3, or 4 who are over 18 years old.
Read more

Harvoni Fact Sheet

  • Chad Cipiti
Harvoni is two HCV-fighting drugs (sofosbuvir and ledipasvir) in one pill. In the United States, Harvoni is approved for HIV-negative and HIV-positive people with hepatitis C genotypes 1, 4, 5, and 6 who are over 18 years old.
Read more

The Low Cost of Universal Access

  • Chad Cipiti

Generic treatments for HIV, viral hepatitis, and cancer can be affordably—and profitably—mass-produced for broad, unobstructed availability By Tracy Swan TAG talks with Andrew Hill, senior visiting research fellow in the University of Liverpool’s Department of Pharmacology, about his group’s work…

Read more

Greed and the Necessity for Regulation

  • Chad Cipiti

The story of U.S. drug pricing run amok isn’t just about corporate arrogance and avarice—it is also about government permissiveness and inaction By Tim Horn, Erica Lessem, and Kenyon Farrow On December 1, 2015, the U.S. Senate Finance Committee issued…

Read more
Back To Top